In summary, we here found out from FDA-approved drug library that luteolin emerged as a therapeutic candidate for pathological cardiac hypertrophy and heart failure by directly suppressing ubiquitin-proteasomal degradation of PPARγ and metabolic homeostasis. The gene discussed is PPARG; the disease is cardiac hypertrophy.